Comparison between Urine and Cervical Samples for HPV DNA detection and typing in young women in Colombia

Cancer Prevention Research

Volumn 9, Issue 9, 2016, Pages 766-771

  Combita, Alba Lucía ^a,b   Gheit, Tarik ^c   Gonzalez, Paula ^d   Puerto, Devi ^a   Murillo, Raul Hernando ^a,c   Montoya, Luisa ^a   Vorsters, Alex ^e   Van Keer, Severien ^e   Van Dammeaa, Pierre ^e   Tommasino, Massimo ^c   Hernandez Suarez, Gustavo ^a   Sanchez, Laura ^a   Herrero, Rolando ^c   Wiesner, Carolina ^a  

^a Instituto Nacional de Cancerología   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ACCURACY; ADULT; ARTICLE; CLINICAL EVALUATION; COLOMBIA; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MCNEMAR TEST; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOFTWARE; STATISTICAL ANALYSIS; URINE; UTERINE CERVIX; VACCINATION; VIRUS DETECTION; VIRUS TYPING; WART VIRUS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; VAGINA SMEAR; VIROLOGY; YOUNG ADULT;

ADULT; CERVIX UTERI; COLOMBIA; DNA, VIRAL; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; URINE; VAGINAL SMEARS; YOUNG ADULT;

EID: 84987858976     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-16-0038     Document Type: Article

References (45)

1. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
2. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
3. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012;7:38.
4. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196:1438-46.
5. Ault KA. Human papillomavirus vaccines and the potential for crossprotection between related HPV types. Gynecol Oncol 2007;107:S31-S33.
6. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines 2014;13:1279-90.
7. De CN, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55.
8. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011;7:1359-73.
9. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
10. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
11. Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 2011;12:862-70.
12. Luxembourg A, Moreira ED, Jr., Samakoses R, Kim K-H, Sun X, Maansson R, et al. Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine. Hum Vaccin Immunother 2015;11:1306-12.
13. Nygard M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol 2015;22:943-8.
14. Pitisuttithum P, Velicer C, Luxembourg A. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Rev Vaccines 2015;1-15.
15. Roteli-Martins CM, Naud P, De BP, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012;8:390-7.
16. Van DP, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics 2015;136:e28-e39.
17. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of followup. Br J Cancer 2006;95:1459-66.
18. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
19. Enerly E, Olofsson C, Nygard M. Monitoring human papillomavirus prevalence in urine samples: a review. Clin Epidemiol 2013;5:67-79.
20. Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van DP. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis 2012;31:627-40.
21. Vorsters A, Van KS, Van DP. The use of urine in the follow-up of HPV vaccine trials. Hum Vaccin Immunother 2015;11:350-2.
22. Jong E, Mulder JW, van Gorp EC, Wagenaar JK, Derksen J, Westerga J, et al. The prevalence of human papillomavirus (HPV) infection in paired urine and cervical smear samples of HIV-infected women. J Clin Virol 2008; 41:111-5.
23. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol 2010;48:143-9.
24. Vorsters A, Van den Bergh J, Micalessi I, Biesmans S, Bogers J, Hens A, et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis 2014;33:2005-14.
25. Vorsters A, Van DP, Clifford G. Urine testing for HPV: rationale for using first void. BMJ 2014;349:g6252.
26. Franceschi S, Chantal Umulisa M, Tshomo U, Gheit T, Baussano I, Tenet V, et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. Int J Cancer 2016;139:518-26.
27. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-12.
28. Gheit T, Landi S, Gemignani F, Snijders PJ, Vaccarella S, Franceschi S, et al. Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol 2006;44:2025-31.
29. Gheit T, Tommasino M. Detection of high-risk mucosal human papillomavirus DNA in human specimens by a novel and sensitive multiplex PCR method combined with DNA microarray. Methods Mol Biol 2011;665: 195-212.
30. Burroni E, Bonanni P, Sani C, Lastrucci V, Carozzi F, Hpv ScreeVacc Working Group, et al. Human papillomavirus prevalence in paired urine and cervical samples in women invited for cervical cancer screening. J Med Virol 2015;87:508-15.
31. Ducancelle A, Legrand MC, Pivert A, Veillon P, Le Guillou-Guillemette H, De Brux MA, et al. Interest of human papillomavirus DNA quantification and genotyping in paired cervical and urine samples to detect cervical lesions. Arch Gynecol Obstet 2014;290:299-308.
32. Nicolau P, Mancebo G, Agramunt S, Sole-Sedẽno JM, Bellosillo B, Muset MM, et al. Urine human papillomavirus prevalence in women with highgrade cervical lesions. Eur J Obstet Gynecol Reprod Biol 2014;183:12-5.
33. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 2014;349:g5264.
34. Giambi C, Donati S, Carozzi F, Salmaso S, Declich S, Atti ML, et al. A crosssectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years. BMC Infect Dis 2013;13:74.
35. Monsonego J, Zerat L, Syrjanen K, Zerat JC, Smith JS, Halfon P. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines. Vaccine 2012;30:5215-21.
36. Panatto D, Amicizia D, Tanzi E, Bianchi S, Frati ER, Zotti CM, et al. Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy? BMC Infect Dis 2013;13:575.
37. Cuschieri K, Nandwani R, McGough P, Cook F, Hogg L, Robertson C, et al. Urine testing as a surveillance tool to monitor the impact of HPV immunization programs. J Med Virol 2011;83:1983-7.
38. Ramqvist T, Du J, Lunden M, Ahrlund-Richter S, Ferreira J, Marions L, et al. Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15-23-year-old women attending a youth health clinic in Stockholm, Sweden. Scand J Infect Dis 2011;43:115-21.
39. Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer 2013;132:198-207.
40. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de SS. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010;202: 1789-99.
41. Bernal S, Palomares JC, Artura A, Parra M, Cabezas JL, Robles A, et al. Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test. J Clin Virol 2014; 61:548-52.
42. Sahasrabuddhe VV, Gravitt PE, Dunn ST, Robbins D, Brown D, Allen RA, et al. Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. J Clin Virol 2014;60:414-7.
43. Bissett SL, Howell-Jones R, Swift C, De Silva N, Biscornet L, Parry JV, et al. Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol 2011;83: 1744-51.
44. Payan C, Ducancelle A, Aboubaker MH, Caer J, Tapia M, Chauvin A, et al. Human papillomavirus quantification in urine and cervical samples by using the Mx4000 and LightCycler general real-time PCR systems. J Clin Microbiol 2007;45:897-901.
45. Tanzi E, Bianchi S, Fasolo MM, Frati ER, Mazza F, Martinelli M, et al. High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping. J Med Virol 2013;85:91-8.